Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, October 29, 2015
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes ...
read more
Monday, February 01, 2016
Bristol-Myers Squibb Company and Pfizer have announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, ...
read more
BlueTheory Clinical Trials, a clinical research network company headquartered in Boston, Massachusetts has been partnering with pharmaceutical and contract research organizations (CROs) to bring treatments and devices to the market since its ...
read more
bluebird bio and Regeneron announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer.
read more
Thursday, August 23, 2018
bluebird bio and Gritstone Oncology announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
read more
Wednesday, January 13, 2021
bluebird bio announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly traded companies.
read more
Monday, December 19, 2016
bluebird bio and apceth Biopharma GmbH have entered into a strategic manufacturing agreement providing for the future European commercial production of bluebird bio’s Lenti-D™ product candidate for cerebral adrenoleukodystropy and its LentiGlobin™ ...
read more
Wednesday, November 29, 2017
bluebird bio has acquired a 125,000-square foot manufacturing facility in Durham, North Carolina.
read more
Bluebee announced a strategic partnership to provide customers with tailored end-to-end analytical solutions for Next Generation Sequencing data.
read more
Blue Water Vaccines has signed an agreement with Ology Bioservices to manufacture a novel universal influenza vaccine.
read more
Blue Water Vaccines announced a novel virus-like particle (VLP) vaccine platform from Cincinnati Children's Hospital Medical Center (Cincinnati Children's). The platform utilizes nanoparticle delivery technology that has the potential for broad ...
read more
Monday, December 11, 2017
Blue Oak Pharmaceuticals and PGI Drug Discovery have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions
read more
Thursday, November 18, 2021
BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience is pleased to announce a collaboration to manufacture ...
read more
Thursday, December 03, 2015
Biovista has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista's Clinical Outcome Search Space (COSS) ...
read more
Thursday, February 01, 2024
Biovian and 3P Biopharmaceuticals (“3P”), two biologics Contract Development and Manufacturing Organizations (CDMOs), announced their combination to establish a new pan-European leader in their field.
read more